Sparine

(chlorpromazine and promethazine)

Phase 1Small molecule

WWyeth-Lederle Vaccines

Sparine is one of 3 small molecule programs targeting Thrombectomy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

ThrombectomyRecruiting

ThrombectomyPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Thrombectomy

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

3 2

Sparine

WWyeth-Lederle Vaccines

Phase 1

1 3

Rt-PA

Boehringer Ingelheim

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thrombectomy1 trial

Study on Hibernation-like Therapy Based on Mechanical Thrombectomy

Recruiting·—·Phase 1·NCT06663631·32 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

SPARINE

NDA NDA010942

Jan 1, 1982

SPARINE

NDA NDA010349

Jan 1, 1982

SPARINE

NDA NDA010348

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for chlorpromazine and promethazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chlorpromazine and promethazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chlorpromazine and promethazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA010942). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wyeth-Lederle Vaccines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWyeth-Lederle Vaccines

Sparine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thrombectomy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News